LFB USA
Lionel Murray has extensive work experience in the pharmaceutical industry. Lionel is currently the Senior Vice President of Quality at LFB USA and previously held the position of Vice President of Quality/Senior Executive Advisor at Neurotech Pharmaceuticals, Inc. Lionel also worked as an Executive Consultant and Scientist at White Otter Group for over 20 years. In addition, they held various quality leadership roles at Shire Pharmaceuticals, Associates of Cape Cod, Inc. (a Seikagaku Pharmaceuticals Company), Amgen, Alkermes, Schwarz Pharma, and Bayer. Lionel has expertise in product quality, operations management, and research and development. Lionel has demonstrated leadership skills and a strong background in pharmaceutical manufacturing and quality control.
Lionel Murray's education history begins in 1976 when they enrolled at UC Irvine and obtained a Bachelor of Science degree in Chemistry, which they completed in 1980. Lionel then pursued further studies, earning a Master of Science degree in Physical Chemistry from the University of California, Riverside between 1980 and 1982.
In 1984, Murray enrolled at Carnegie Mellon University to pursue a Ph.D. in Biophysical Chemistry, which they completed in 1985. Lionel took a break from their academic pursuits for a few years before undertaking additional education in 1997 at Harvard University. The details of this short-term education, including the degree and field of study, are unknown.
Murray's educational journey continued in 2007 at the University of Maryland Global Campus, although specific details about the degree and field of study are also unavailable.
This person is not in any offices
LFB USA
Company Profile LFB USA, Inc. is a privately held biotechnology company in the Boston, Massachusetts area with headquarters and laboratories in Framingham, MA and production operations in Charlton, MA. LFB USA is a company within the LFB Group. LFB USA provides development, manufacturing and services to LFB S.A., its sister company rEVO Biologics, and other partners. One of the lead projects of LFB S.A. is the recombinant human Factor FVIIa (LR769) program. LFB USA is responsible for the upstream manufacturing of the recombinant protein and the Clinical and Regulatory aspects of the program. LR769 is currently being evaluated in a Phase 3 study in adults with congenital hemophilia A or B with inhibitors. LFB USA’s principal goal is to advance medical care by utilizing its proprietary technology to develop its own programs and assist its partners by providing a full range of services. LFB USA is currently looking for motivated scientific, business and healthcare professionals with an entrepreneurial spirit. For more information about LFB USA please visit www.lfb-usa.com Company Background LFB USA, Inc. was formed as a subsidiary of LFB Biotechnologies in April, 2014 as the result of a carve-out of rEVO Biologics, Inc.